Merit Medical Systems (NASDAQ:MMSI – Get Rating) had its price objective raised by Barrington Research from $78.00 to $82.00 in a research report released on Friday morning, The Fly reports. The firm currently has a buy rating on the medical instruments supplier’s stock. Barrington Research also issued estimates for Merit Medical Systems’ Q1 2022 earnings at $0.56 EPS, Q2 2022 earnings at $0.72 EPS, Q3 2022 earnings at $0.60 EPS, Q4 2022 earnings at $0.66 EPS, FY2022 earnings at $2.55 EPS and FY2023 earnings at $2.85 EPS.

MMSI has been the topic of a number of other research reports. Piper Sandler cut their price target on shares of Merit Medical Systems from $79.00 to $75.00 in a report on Friday. Raymond James lowered their price objective on shares of Merit Medical Systems from $73.00 to $72.00 and set an outperform rating on the stock in a research report on Friday. Needham & Company LLC lowered their price objective on shares of Merit Medical Systems from $83.00 to $73.00 and set a buy rating on the stock in a research report on Friday. Finally, Wells Fargo & Company increased their price objective on shares of Merit Medical Systems from $68.00 to $74.00 and gave the company an equal weight rating in a research report on Friday, October 29th. One equities research analyst has rated the stock with a hold rating and four have given a buy rating to the company’s stock. According to MarketBeat.com, Merit Medical Systems has a consensus rating of Buy and a consensus price target of $75.20.

NASDAQ:MMSI opened at $64.55 on Friday. The company’s 50 day moving average price is $58.75 and its 200-day moving average price is $65.34. Merit Medical Systems has a 52 week low of $51.66 and a 52 week high of $73.85. The company has a quick ratio of 1.20, a current ratio of 2.17 and a debt-to-equity ratio of 0.27. The stock has a market cap of $3.64 billion, a price-to-earnings ratio of 75.94, a PEG ratio of 2.34 and a beta of 1.15.

Merit Medical Systems (NASDAQ:MMSI – Get Rating) last posted its quarterly earnings results on Thursday, February 24th. The medical instruments supplier reported $0.71 EPS for the quarter, beating the Zacks’ consensus estimate of $0.51 by $0.20. Merit Medical Systems had a net margin of 4.51% and a return on equity of 13.70%. The firm had revenue of $278.50 million for the quarter, compared to analysts’ expectations of $270.96 million. During the same quarter in the prior year, the company posted $0.54 earnings per share. The business’s revenue for the quarter was up 7.9% on a year-over-year basis. As a group, sell-side analysts anticipate that Merit Medical Systems will post 2.4 earnings per share for the current year.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. BlackRock Inc. raised its position in Merit Medical Systems by 10.8% in the fourth quarter. BlackRock Inc. now owns 8,334,516 shares of the medical instruments supplier’s stock worth $519,240,000 after acquiring an additional 809,628 shares during the period. Conestoga Capital Advisors LLC raised its position in shares of Merit Medical Systems by 4.9% during the 4th quarter. Conestoga Capital Advisors LLC now owns 2,510,787 shares of the medical instruments supplier’s stock valued at $156,422,000 after purchasing an additional 117,795 shares during the period. State Street Corp raised its position in shares of Merit Medical Systems by 3.2% during the 4th quarter. State Street Corp now owns 1,914,449 shares of the medical instruments supplier’s stock valued at $119,270,000 after purchasing an additional 58,884 shares during the period. Macquarie Group Ltd. raised its position in shares of Merit Medical Systems by 1.0% during the 3rd quarter. Macquarie Group Ltd. now owns 1,439,274 shares of the medical instruments supplier’s stock valued at $103,340,000 after purchasing an additional 14,291 shares during the period. Finally, Westwood Holdings Group Inc. raised its position in shares of Merit Medical Systems by 40.1% during the 4th quarter. Westwood Holdings Group Inc. now owns 1,182,149 shares of the medical instruments supplier’s stock valued at $73,648,000 after purchasing an additional 338,655 shares during the period. Institutional investors and hedge funds own 95.93% of the company’s stock.

About Merit Medical Systems (Get Rating)

Merit Medical Systems, Inc engages in the manufacture and marketing of proprietary disposable medical devices. It operates through the Cardiovascular and Endoscopy segments. The Cardiovascular segment consists of peripheral intervention, cardiac intervention, interventional oncology and spine, and cardiovascular and critical care product groups.

See Also

Want More Great Investing Ideas?

Receive News & Ratings for Merit Medical Systems Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Merit Medical Systems and related companies with MarketBeat.com’s FREE daily email newsletter.

Merit Medical Systems (NASDAQ:MMSI – Get Rating) had its price objective raised by Barrington Research from $78.00 to $82.00 in a research report released on Friday morning, The Fly reports. The firm currently has a buy rating on the medical instruments supplier’s stock. Barrington Research also issued estimates for Merit Medical Systems’ Q1 2022 earnings at $0.56 EPS, Q2 2022 earnings at $0.72 EPS, Q3 2022 earnings at $0.60 EPS, Q4 2022 earnings at $0.66 EPS, FY2022 earnings at $2.55 EPS and FY2023 earnings at $2.85 EPS.

MMSI has been the topic of a number of other research reports. Piper Sandler cut their price target on shares of Merit Medical Systems from $79.00 to $75.00 in a report on Friday. Raymond James lowered their price objective on shares of Merit Medical Systems from $73.00 to $72.00 and set an outperform rating on the stock in a research report on Friday. Needham & Company LLC lowered their price objective on shares of Merit Medical Systems from $83.00 to $73.00 and set a buy rating on the stock in a research report on Friday. Finally, Wells Fargo & Company increased their price objective on shares of Merit Medical Systems from $68.00 to $74.00 and gave the company an equal weight rating in a research report on Friday, October 29th. One equities research analyst has rated the stock with a hold rating and four have given a buy rating to the company’s stock. According to MarketBeat.com, Merit Medical Systems has a consensus rating of Buy and a consensus price target of $75.20.

NASDAQ:MMSI opened at $64.55 on Friday. The company’s 50 day moving average price is $58.75 and its 200-day moving average price is $65.34. Merit Medical Systems has a 52 week low of $51.66 and a 52 week high of $73.85. The company has a quick ratio of 1.20, a current ratio of 2.17 and a debt-to-equity ratio of 0.27. The stock has a market cap of $3.64 billion, a price-to-earnings ratio of 75.94, a PEG ratio of 2.34 and a beta of 1.15.

Merit Medical Systems (NASDAQ:MMSI – Get Rating) last posted its quarterly earnings results on Thursday, February 24th. The medical instruments supplier reported $0.71 EPS for the quarter, beating the Zacks’ consensus estimate of $0.51 by $0.20. Merit Medical Systems had a net margin of 4.51% and a return on equity of 13.70%. The firm had revenue of $278.50 million for the quarter, compared to analysts’ expectations of $270.96 million. During the same quarter in the prior year, the company posted $0.54 earnings per share. The business’s revenue for the quarter was up 7.9% on a year-over-year basis. As a group, sell-side analysts anticipate that Merit Medical Systems will post 2.4 earnings per share for the current year.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. BlackRock Inc. raised its position in Merit Medical Systems by 10.8% in the fourth quarter. BlackRock Inc. now owns 8,334,516 shares of the medical instruments supplier’s stock worth $519,240,000 after acquiring an additional 809,628 shares during the period. Conestoga Capital Advisors LLC raised its position in shares of Merit Medical Systems by 4.9% during the 4th quarter. Conestoga Capital Advisors LLC now owns 2,510,787 shares of the medical instruments supplier’s stock valued at $156,422,000 after purchasing an additional 117,795 shares during the period. State Street Corp raised its position in shares of Merit Medical Systems by 3.2% during the 4th quarter. State Street Corp now owns 1,914,449 shares of the medical instruments supplier’s stock valued at $119,270,000 after purchasing an additional 58,884 shares during the period. Macquarie Group Ltd. raised its position in shares of Merit Medical Systems by 1.0% during the 3rd quarter. Macquarie Group Ltd. now owns 1,439,274 shares of the medical instruments supplier’s stock valued at $103,340,000 after purchasing an additional 14,291 shares during the period. Finally, Westwood Holdings Group Inc. raised its position in shares of Merit Medical Systems by 40.1% during the 4th quarter. Westwood Holdings Group Inc. now owns 1,182,149 shares of the medical instruments supplier’s stock valued at $73,648,000 after purchasing an additional 338,655 shares during the period. Institutional investors and hedge funds own 95.93% of the company’s stock.

About Merit Medical Systems (Get Rating)

Merit Medical Systems, Inc engages in the manufacture and marketing of proprietary disposable medical devices. It operates through the Cardiovascular and Endoscopy segments. The Cardiovascular segment consists of peripheral intervention, cardiac intervention, interventional oncology and spine, and cardiovascular and critical care product groups.

See Also

Want More Great Investing Ideas?

Receive News & Ratings for Merit Medical Systems Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Merit Medical Systems and related companies with MarketBeat.com’s FREE daily email newsletter.